{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T16:49:25Z","timestamp":1712076565263},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T00:00:00Z","timestamp":1549238400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s40618-019-01015-8","type":"journal-article","created":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T19:21:44Z","timestamp":1549308104000},"page":"351-352","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Can combination of glucocorticoids with other immunosoppressive drugs reduce the cumulative dose of glucocorticoids for moderate-to-severe and active Graves\u2019 orbitopathy?"],"prefix":"10.1007","volume":"42","author":[{"given":"M. L.","family":"Tanda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Piantanida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Masiello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Cusini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Bartalena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,4]]},"reference":[{"key":"1015_CR1","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s40618-014-0097-2","volume":"37","author":"L Bartalena","year":"2014","unstructured":"Bartalena L, Fatourechi V (2014) Extrathyroidal manifestations of Graves\u2019 disease: a 2014 update. J Endocrinol Invest 37:691\u2013700","journal-title":"J Endocrinol Invest"},{"key":"1015_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000443828","volume":"5","author":"L Bartalena","year":"2016","unstructured":"Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WM, on behalf of the European Group on Graves\u2019 Orbitopathy (EUGOGO) (2016) The 2016 European Thyroid Association\/European group on Graves\u2019 orbitopathy Guidelines for the management of Graves\u2019 orbitopathy. Eur Thyroid J 5:9\u201326","journal-title":"Eur Thyroid J"},{"key":"1015_CR3","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJM198911163212002","volume":"321","author":"MF Prummel","year":"1989","unstructured":"Prummel MF, Mourits P, Berghout A, Krenning EP, van der Gaag R, Koornneef L, Wiersinga WM (1989) Prednisone and cyclosporine in the treatment of severe Graves\u2019 ophthalmopathy. N Engl J Med 321:1353\u20131359","journal-title":"N Engl J Med"},{"key":"1015_CR4","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.1210\/jc.2012-2758","volume":"97","author":"ML Tanda","year":"2012","unstructured":"Tanda ML, Bartalena L (2012) Efficacy and safety of orbital radiotherapy for Graves\u2019 orbitopathy. J Clin Endocrinol Metab 97:3857\u20133865","journal-title":"J Clin Endocrinol Metab"},{"key":"1015_CR5","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S2213-8587(18)30020-2","volume":"6","author":"GJ Kahaly","year":"2018","unstructured":"Kahaly GJ, Riedl M, Konig J, Pitz S, Ponto K, Diana T, Kampmann E, Kolbe E, Eckstein A, Moeller LC, Fuhrer D, Salvi M, Curr\u00f2 N, Campi I, Covelli D, Leo M, Marin\u00f2 M, Menconi F, Marcocci C, Bartalena L, Perros P, Wiersinga WM, for the European Group on Graves\u2019 Orbitopathy (EUGOGO) (2018) Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves\u2019 orbitopathy (MINGO): a randomized, observer-masked, multicentre study. Lancet Diabetes Endocrinol 6:287\u2013298","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1015_CR6","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S2213-8587(18)30021-4","volume":"6","author":"R Rajendram","year":"2018","unstructured":"Rajendram R, Taylor PN, Wilson VJ, Harris N, Morris OC, Tomlinson M, Yarrow S, Garrott H, Herbert HM, Dick AD, Cook A, Gattamaneni R, Jain R, Olver J, Hurel SJ, Bremner F, Drummond SR, Kemp E, Ritchie BM, RumsEy N, Morris D, Lane C, Palanappian N, Li C, Pell J, Hills R, Ezra DG, Potts MJ, Jackson S, Rose GE, Plowman N, Bunce C, Uddin JM, Lee RWJ, Dayan CM (2018) Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2\u00a0\u00d7\u00a02 factorial, double-blind, randomized controlled trial. Lancet Diabetes Endocrinol 6:299\u2013309","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1015_CR7","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1111\/cen.13834","volume":"89","author":"Z Sipkova","year":"2018","unstructured":"Sipkova Z, Insull EA, David J, Turner HE, Karen S, Norris JH (2018) Early use of steroid-sparing agents in the inactivation of moderate-to-severe active thyroid eye disease: a step-down approach. Clin Endocrinol 89:834\u2013839","journal-title":"Clin Endocrinol"},{"key":"1015_CR8","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s40618-017-0717-8","volume":"40","author":"E Piantanida","year":"2017","unstructured":"Piantanida E, Bartalena L (2017) Teprotumumab: a new avenue for the management of moderate-to-severe and active Graves\u2019 orbitopathy? J Endocrinol Invest 40:885\u2013887","journal-title":"J Endocrinol Invest"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40618-019-01015-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-019-01015-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-019-01015-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T00:18:23Z","timestamp":1580775503000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40618-019-01015-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,4]]},"references-count":8,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["1015"],"URL":"https:\/\/doi.org\/10.1007\/s40618-019-01015-8","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,4]]},"assertion":[{"value":"24 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This paper did not involve patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}